Unicycive Therapeutics Faces Securities Lawsuit
Analysis based on 9 articles · First reported Aug 22, 2025 · Last updated Sep 30, 2025
The market is negatively impacted by the news of Unicycive Therapeutics facing a securities class action lawsuit, as its stock price significantly dropped following the United States — Food and Drug Administration's findings. This event highlights regulatory risks in the pharmaceutical industry, potentially leading investors to scrutinize other companies' manufacturing compliance more closely.
Faruqi & Faruqi, a national securities law firm, is investigating Unicycive Therapeutics, Inc. and encouraging investors to join a federal securities class action lawsuit. The lawsuit alleges that Unicycive Therapeutics and its executives made false and misleading statements regarding the company's ability to meet the United States — Food and Drug Administration's manufacturing compliance requirements and the regulatory prospects of its OLC NDA. On June 10, 2025, Unicycive Therapeutics disclosed that the United States — Food and Drug Administration had identified cGMP deficiencies at a third-party manufacturing vendor, precluding label discussions. This news caused Unicycive Therapeutics' stock price to fall by 40.89%. Subsequently, on June 30, 2025, Unicycive Therapeutics announced that the United States — Food and Drug Administration issued a Complete Response Letter for the OLC NDA, citing the same deficiencies, leading to another 29.85% drop in stock price. James Wilson of Faruqi & Faruqi is leading the effort to gather affected investors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard